Ensuring Access to Lower-Cost Medicines for Seniors Act of 2026.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Summary
The bill forces Medicare Part D prescription‑drug plans that use a formulary to include any lower‑cost generic drug and at least two lower‑cost biosimilar products in a preferred position on the formulary. Plan sponsors may not apply stricter prior‑authorization or step‑therapy rules to those drugs than they do to the brand‑name reference products. The goal is to lower seniors’ out‑of‑pocket costs and expand access to affordable medicines.
AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.
Topics
Track this bill
Get real-time alerts when HR 8143 changes status, plus AI-powered summaries and stage predictions.
Sign up free